Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
Type:
Grant
Filed:
September 17, 2019
Date of Patent:
August 15, 2023
Assignees:
Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Científicas y Técnicas (CONICET), Fundacion Sales
Inventors:
Margaret Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
Type:
Grant
Filed:
January 16, 2015
Date of Patent:
October 29, 2019
Assignees:
Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
Inventors:
Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
Type:
Grant
Filed:
November 26, 2014
Date of Patent:
May 21, 2019
Assignees:
INIS Biotech LLC, Consejo Nacional de Investigaciones Cientificas Y Tecnicas, Fundacion Sales
Inventors:
Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino
Abstract: The present invention provides methods and compositions for treating cancer patients, and in particular, breast cancer patients, who are responsive to antiprogestin therapy, or who may be induced to be responsive to an antiprogestin therapy through the administration of a demethylation agent, optionally together with an HDAC inhibitor. Further, the present invention relates to a method of screening cancer patients using BCL-XL as a marker protein.
Type:
Grant
Filed:
December 7, 2012
Date of Patent:
August 7, 2018
Assignee:
FUNDACION SALES
Inventors:
Claudia L. Lanari, Victoria Wargon, Paola Rojas, Maria May, Gonzalo Sequeira
Abstract: Galectin-1 polypeptide variants that include a mutation of the histidine residue corresponding to position 52 of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the mutation being a substitution of the histidine to tyrosine or asparagine, providing resistance to acidosis otherwise resulting in deactivation of the native human Gal-1. The Galectin-1 polypeptide variants may include one or more additional mutation(s) of the cysteine residue corresponding to a position selected from 2, 16, 88, or combinations thereof of the full-length amino acid sequence of native human Gal-1 as shown in SEQ ID NO: 1, the additional mutation being a substitution of the cysteine to serine, and providing resistance to oxidation.
Type:
Grant
Filed:
April 21, 2016
Date of Patent:
June 19, 2018
Assignees:
Consejo Nacional de Investigaciones Cientificas Y Técnicas, Fundación Sales, INIS Biotech LLC
Inventors:
Gabriel Adrián Rabinovich, Santiago Di Lella, Dario Ariel Estrin, Julio Javier Carmelo, Santiago Patricio Mendez Huergo
Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring immune disorders, e.g., Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL+ pre B-cell ALL.
Type:
Grant
Filed:
July 17, 2008
Date of Patent:
April 10, 2018
Assignees:
Dana-Farber Cancer Institute, Inc., Consejo Nactional De Investigaciones Cientificias Y Tecnicas, Fundacion Sales
Inventors:
Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.
Type:
Grant
Filed:
July 17, 2008
Date of Patent:
December 8, 2015
Assignees:
Dana-Farber Cancer Institute, Inc., CONICET, Fundacion Sales
Inventors:
Margaret A. Shipp, Przemyslaw Juszczynski, Jing Ouyang, Jeffery Kutok, Scott Rodig, Gabriel Rabinovich
Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
Type:
Application
Filed:
January 16, 2015
Publication date:
July 9, 2015
Applicants:
The Brigham and Women's Hospital, Inc., Consejo Nacional De Investigaciones Cientificias Y Tecnicas, Fundacion Sales
Inventors:
Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
Type:
Grant
Filed:
November 12, 2010
Date of Patent:
March 3, 2015
Assignees:
Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
Inventors:
Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
Abstract: In spite of their pivotal role in orchestrating immunity, dendritic cells (DCs) may be licensed by immunosuppressive signals to become tolerogenic. Here we show that ligation of cell surface glyco-receptors by Galectin-1, an endogenous glycan-binding protein, can drive the differentiation of regulatory DCs with tolerogenic potential in vivo. Galectin-1-differentiated DCs acquired a tolerogenic phenotype characterized by IL-27-dependent, STAT3-mediated and CD45RB+IL-10+ regulatory signatures. Adoptive transfer of galectin-1-conditioned DCs induced T-cell tolerance in inflammatory and neoplastic settings and dampened TH1- and TH-17-mediated autoimmune neuroinflammation. Consistent with a negative regulatory function of endogenous galectin-1, DCs from galectin-1-deficient (Lgals1?/?) mice had greater immunogenic capacity compared with their wild-type counterparts.
Type:
Application
Filed:
June 11, 2008
Publication date:
January 1, 2009
Applicants:
CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET), FUNDACION SALES
Inventors:
Gabriel Adrian Rabinovich, Juan Martin Ilarregui, Marta Alicia Toscano, German Ariel Bianco